These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 26495067)

  • 1. Drug therapy of overactive bladder--what is coming next?
    Andersson KE
    Korean J Urol; 2015 Oct; 56(10):673-9. PubMed ID: 26495067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging drugs for overactive bladder.
    Karmarkar R; Khullar V
    Expert Opin Emerg Drugs; 2015; 20(4):613-24. PubMed ID: 26359223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential Future Pharmacological Treatment of Bladder Dysfunction.
    Andersson KE
    Basic Clin Pharmacol Toxicol; 2016 Oct; 119 Suppl 3():75-85. PubMed ID: 26990140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Latest treatment for lower urinary tract dysfunction: therapeutic agents and mechanism of action.
    Yamaguchi O
    Int J Urol; 2013 Jan; 20(1):28-39. PubMed ID: 23190275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. β3-Adrenoceptor Control of Lower Genitourinary Tract Organs and Function in Male: An Overview.
    Kaya E; Sikka SC; Oral DY; Ozakca I; Gur S
    Curr Drug Targets; 2018; 19(6):602-612. PubMed ID: 28117002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of overactive bladder symptoms beyond antimuscarinics: current and future therapies.
    Ellsworth P
    Postgrad Med; 2012 May; 124(3):16-27. PubMed ID: 22691895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A drug safety evaluation of mirabegron in the management of overactive bladder.
    Robinson D; Thiagamoorthy G; Cardozo L
    Expert Opin Drug Saf; 2016 May; 15(5):689-96. PubMed ID: 26980445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Botulinum toxin A for the Treatment of Overactive Bladder.
    Hsieh PF; Chiu HC; Chen KC; Chang CH; Chou EC
    Toxins (Basel); 2016 Feb; 8(3):. PubMed ID: 26938559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Understanding clinic options for overactive bladder.
    Bartley JM; Blum ES; Sirls LT; Peters KM
    Curr Urol Rep; 2013 Dec; 14(6):541-8. PubMed ID: 23812967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Innovative pharmacotherapies for women with overactive bladder: where are we now and what is in the pipeline?
    Sacco E; Bientinesi R
    Int Urogynecol J; 2015 May; 26(5):629-40. PubMed ID: 25377296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current and future pharmacotherapy for treating overactive bladder.
    Thiagamoorthy G; Cardozo L; Robinson D
    Expert Opin Pharmacother; 2016 Jul; 17(10):1317-25. PubMed ID: 27253972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination therapy with β3 -adrenoceptor agonists and muscarinic acetylcholine receptor antagonists: Efficacy in rats with bladder overactivity.
    Furuta A; Suzuki Y; Kimura S; Koike Y; Egawa S; Yoshimura N
    Int J Urol; 2016 May; 23(5):425-30. PubMed ID: 26890938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Idiopathic overactive bladder: What to do in case of anticholinergic failure?].
    Boudy AS; Thubert T
    Prog Urol; 2015 Jun; 25(8):497-8. PubMed ID: 25748787
    [No Abstract]   [Full Text] [Related]  

  • 14. Mirabegron: A new option in treating overactive bladder.
    Turpen HC; Zimmern PE
    JAAPA; 2015 Nov; 28(11):16, 18. PubMed ID: 26501573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).
    Abrams P; Kelleher C; Staskin D; Rechberger T; Kay R; Martina R; Newgreen D; Paireddy A; van Maanen R; Ridder A
    Eur Urol; 2015 Mar; 67(3):577-88. PubMed ID: 24612659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Not Available].
    Bywater M; Kessler TM
    Praxis (Bern 1994); 2017; 106(21):1175-1181. PubMed ID: 29041854
    [No Abstract]   [Full Text] [Related]  

  • 17. Antimuscarinics, β-3 Agonists, and Phosphodiesterase Inhibitors in the Treatment of Male Lower Urinary Tract Symptoms: An Evolving Paradigm.
    Osman NI; Aldamanhori R; Mangera A; Chapple CR
    Urol Clin North Am; 2016 Aug; 43(3):337-49. PubMed ID: 27476126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacotherapy of the overactive bladder.
    Andersson KE
    Discov Med; 2009 Oct; 8(42):118-24. PubMed ID: 19833057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in the United Kingdom.
    Nazir J; Maman K; Neine ME; Briquet B; Odeyemi IA; Hakimi Z; Garnham A; Aballéa S
    Value Health; 2015 Sep; 18(6):783-90. PubMed ID: 26409605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early investigational β3 adreno-receptor agonists for the management of the overactive bladder syndrome.
    Thiagamoorthy G; Giarenis I; Cardozo L
    Expert Opin Investig Drugs; 2015; 24(10):1299-306. PubMed ID: 26292923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.